We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+5.97%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$194M
AUM Growth
+$4.56M
Cap. Flow
+$124K
Cap. Flow %
0.06%
Top 10 Hldgs %
92.1%
Holding
47
New
6
Increased
8
Reduced
4
Closed
7

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$1.44M
2
CFRX
ContraFect Corporation
CFRX
+$485K
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$463K
4
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$360K
5
XLRN
Acceleron Pharma
XLRN
+$347K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$1.91M
2
NXTM
NxStage Medical Inc.
NXTM
+$857K
3
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$727K
4
ADXS
Advaxis Inc
ADXS
+$231K
5
OPK icon
Opko Health
OPK
+$159K

Sector Composition

Rank Sector Weight
1 Healthcare 96.21%
2 Energy 2.46%
3 Industrials 0.44%
4 Consumer Staples 0.37%
5 Consumer Discretionary 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$111M 57.33%
761,051
-14,000
-2% -$1.91M
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$49M 25.32%
218,380
– –
VRML
3
DELISTED
Vermillion, Inc.
VRML
$4.43M 2.29%
2,462,933
+180,000
+8% +$265K
NBIX icon
4
Neurocrine Biosciences
NBIX
$17.2B
$3.21M 1.66%
52,400
+27,200
+108% +$1.44M
EQT icon
5
EQT Corp
EQT
$31B
$2.76M 1.43%
77,705
– –
CORT icon
6
Corcept Therapeutics
CORT
$9.72B
$1.83M 0.95%
95,000
– –
QDEL icon
7
QuidelOrtho
QDEL
$1.19B
$1.71M 0.88%
38,975
– –
OVV icon
8
Ovintiv
OVV
$16.2B
$1.56M 0.8%
26,460
– –
AAAP
9
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$1.49M 0.77%
22,000
+2,000
+10% +$97.1K
OXFD
10
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$1.3M 0.67%
77,303
+10,000
+15% +$163K
CFRX
11
DELISTED
ContraFect Corporation
CFRX
$1.26M 0.65%
1,419
+513
+57% +$485K
VNDA icon
12
Vanda Pharmaceuticals
VNDA
$327M
$1.22M 0.63%
68,000
– –
VCYT icon
13
Veracyte
VCYT
$4.72B
$1.04M 0.54%
118,767
+20,000
+20% +$163K
SIEN
14
DELISTED
Sientra, Inc.
SIEN
$975K 0.5%
6,330
– –
XLRN
15
DELISTED
Acceleron Pharma
XLRN
$933K 0.48%
25,000
+10,000
+67% +$347K
SITO
16
DELISTED
SITO MOBILE, LTD
SITO
$857K 0.44%
120,000
-20,000
-14% -$95.6K
WMGI
17
DELISTED
Wright Medical Group Inc
WMGI
$776K 0.4%
30,000
– –
BIOL
18
DELISTED
Biolase, Inc.
BIOL
$775K 0.4%
103
– –
YTEN
19
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$722K 0.37%
236
– –
MASI
20
DELISTED
Masimo
MASI
$692K 0.36%
8,000
– –
TSRO
21
DELISTED
TESARO, Inc.
TSRO
$671K 0.35%
5,200
– –
MRK icon
22
Merck
MRK
$315B
$640K 0.33%
10,480
– –
VYGR icon
23
Voyager Therapeutics
VYGR
$192M
$494K 0.26%
+24,000
New +$271K
PXD
24
DELISTED
Pioneer Natural Resource Co.
PXD
$443K 0.23%
3,000
– –
CELGZ
25
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$443K 0.23%
291,877
– –
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Birchview Capital held 47 positions worth $194M, up 2.4% from $189M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Birchview Capital's Q3 2017 filing shows 6 new, 8 increased, 4 reduced and 7 closed positions. Its largest new stake was Intercept Pharmaceuticals, Inc.: 4,300 shares worth $250K. The largest sale was Celgene Corp, an estimated $1.91M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Energy and Industrials.

  • Birchview Capital's largest Q3 2017 buy was Intercept Pharmaceuticals, Inc.: 4,300 shares worth $250K.
  • Birchview Capital added most to Neurocrine Biosciences in Q3 2017, an estimated $1.44M increase.
  • Birchview Capital's biggest Q3 2017 reduction was Celgene Corp, cutting an estimated $1.91M.
  • Birchview Capital fully exited NxStage Medical Inc. in Q3 2017, selling an estimated $857K.
  • Birchview Capital's ten largest holdings make up 92% of its $194M portfolio in Q3 2017.
  • Birchview Capital opened 6 new positions and closed 7 in Q3 2017.
  • Birchview Capital's portfolio value rose 2.4% quarter-over-quarter to $194M.

Based on Birchview Capital's 13F filing for Q3 2017, filed 2 Nov 2017.